High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer

L. A. Holmberg, T. Demirer, S. Rowley, C. D. Buckner, G. Goodman, R. Maziarz, J. Klarnet, N. Zuckerman, G. Harrer, R. McCloskey, R. Gersh, R. Goldberg, W. Nichols, A. Jacobs, P. Weiden, P. Montgomery, S. Rivkin, F. R. Appelbaum, W. I. Bensinger

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

The purpose of this study was to evaluate the efficacy of high-dose chemotherapy (HDC) with busulfan, melphalan and thiotepa (BUMELTT) followed by autologous PBSC infusion in treating patients with advanced ovarian cancer. Thirty-one patients, 18 with stage III/IIIc and 13 with stage IV ovarian cancer, were treated with BU (12 mg/kg), MEL (100 mg/m2) and TT (500 mg/m2) and autologous PBSC rescue. Fifteen patients were in clinical complete remission (CR) at treatment; 11 had platinum-sensitive disease. Sixteen patients were not in CR; two had platinum-sensitive disease. The probabilities of overall survival (OS), event-free survival (EFS) and relapse (R) for all patients at 18 months were 0.57, 0.30 and 0.63; for patients in CR, the rates were 0.87, 0.44 and 0.49 and for patients not in CR, 0.38, 0.13 and 0.81. Two patients (6.5%) died of treatment-related causes. Among the 13 patients with platinum-sensitive disease, all are still alive, with seven having relapsed 129-1021 days after PBSC infusion. OS, EFS and R were 1.00, 0.52 and 0.48. Of the 18 patients with platinum-resistant disease, four remain alive (two in remission). Six patients did not respond and eight relapsed from days 104-429. The OS, EFS and R were 0.33, 0.11 and 0.78. We conclude that BUMELTT is well tolerated in patients with advanced ovarian cancer and results are equivalent to other published HDC regimens.

Original languageEnglish (US)
Pages (from-to)651-659
Number of pages9
JournalBone marrow transplantation
Volume22
Issue number7
DOIs
StatePublished - Jan 1 1998

Keywords

  • Busulfan
  • High-dose chemotherapy
  • Melphalan
  • Ovarian cancer
  • PBSC
  • Thiotepa

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Holmberg, L. A., Demirer, T., Rowley, S., Buckner, C. D., Goodman, G., Maziarz, R., Klarnet, J., Zuckerman, N., Harrer, G., McCloskey, R., Gersh, R., Goldberg, R., Nichols, W., Jacobs, A., Weiden, P., Montgomery, P., Rivkin, S., Appelbaum, F. R., & Bensinger, W. I. (1998). High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone marrow transplantation, 22(7), 651-659. https://doi.org/10.1038/sj.bmt.1701398